Display options
Cite
Fernandes LR, Ribeiro AC, Segatto M, et al. Leishmania major Self-Limited Infection Increases Blood Cholesterol and Promotes Atherosclerosis Development. Cholesterol. 2013;2013:754580doi: 10.1155/2013/754580.
Fernandes, L. R., Ribeiro, A. C., Segatto, M., Santos, L. F., Amaral, J., Portugal, L. R., & Leite, J. I. (2013). Leishmania major Self-Limited Infection Increases Blood Cholesterol and Promotes Atherosclerosis Development. Cholesterol, 2013754580. https://doi.org/10.1155/2013/754580
Fernandes, Luciana R, et al. "Leishmania major Self-Limited Infection Increases Blood Cholesterol and Promotes Atherosclerosis Development." Cholesterol vol. 2013 (2013): 754580. doi: https://doi.org/10.1155/2013/754580
Fernandes LR, Ribeiro AC, Segatto M, Santos LF, Amaral J, Portugal LR, Leite JI. Leishmania major Self-Limited Infection Increases Blood Cholesterol and Promotes Atherosclerosis Development. Cholesterol. 2013;2013:754580. doi: 10.1155/2013/754580. Epub 2013 Apr 28. PMID: 23710353; PMCID: PMC3655479.
Copy Download .nbib Format: NLM
Share it on

Cholesterol. 2013;2013:754580. doi: 10.1155/2013/754580. Epub 2013 Apr 28.

Leishmania major Self-Limited Infection Increases Blood Cholesterol and Promotes Atherosclerosis Development.

Cholesterol

Luciana R Fernandes, Ana Cecília C Ribeiro, Marcela Segatto, Luís Felipe F F Santos, Joana Amaral, Luciane R Portugal, Jacqueline I A Leite

Affiliations

  1. Departamento de Bioquímica e Imunologia, Universidade Federal Minas Gerais, 31270-901 Belo Horizonte, MG, Brazil.

PMID: 23710353 PMCID: PMC3655479 DOI: 10.1155/2013/754580

Abstract

Leishmania major infection of resistant mice causes a self-limited lesion characterized by macrophage activation and a Th1 proinflammatory response. Atherosclerosis is an inflammatory disease involving hypercholesterolemia and macrophage activation. In this study, we evaluated the influence of L. major infection on the development of atherosclerosis using atherosclerosis-susceptible apolipoprotein E-deficient (apoE KO) mice. After 6 weeks of infection, apoE KO mice exhibited reduced footpad swelling and parasitemia similar to C57BL/6 controls, confirming that both strains are resistant to infection with L. major. L. major-infected mice had increased plasma cholesterol levels and reduced triacylglycerols. With regard to atherosclerosis, noninfected mice developed only fatty streak lesions, while the infected mice presented with advanced lesions containing a necrotic core and an abundant inflammatory infiltrate. CD36 expression was increased in the aortic valve of the infected mice, indicating increased macrophage activation. In conclusion, L. major infection, although localized and self-limited in resistant apoE KO mice, has a detrimental effect on the blood lipid profile, increases the inflammatory cell migration to atherosclerotic lesions, and promotes atherogenesis. These effects are consequences of the stimulation of the immune system by L. major, which promotes the inflammatory components of atherosclerosis, which are primarily the parasite-activated macrophages.

References

  1. Nat Rev Immunol. 2002 Nov;2(11):845-58 - PubMed
  2. QJM. 2006 Jan;99(1):1-14 - PubMed
  3. J Biol Chem. 1957 May;226(1):497-509 - PubMed
  4. Trans R Soc Trop Med Hyg. 2002 Apr;96 Suppl 1:S87-92 - PubMed
  5. Immunobiology. 2008;213(3-4):377-87 - PubMed
  6. Circulation. 2001 Feb 27;103(8):1064-70 - PubMed
  7. Br J Pharmacol. 2011 Nov;164(6):1738-48 - PubMed
  8. Vet Parasitol. 1992 Oct;44(3-4):175-82 - PubMed
  9. N Engl J Med. 2005 Apr 21;352(16):1685-95 - PubMed
  10. Atherosclerosis. 1998 Oct;140 Suppl 1:S3-9 - PubMed
  11. Eur J Biochem. 2000 May;267(9):2555-66 - PubMed
  12. Atherosclerosis. 1987 Dec;68(3):231-40 - PubMed
  13. J Nutr. 1993 Nov;123(11):1939-51 - PubMed
  14. Crit Rev Oral Biol Med. 2004 Nov 01;15(6):403-13 - PubMed
  15. Br Heart J. 1995 Nov;74(5):497-501 - PubMed
  16. Clin Nutr. 2005 Feb;24(1):16-31 - PubMed
  17. Infect Immun. 2004 Aug;72(8):4918-23 - PubMed
  18. Clin Vaccine Immunol. 2009 Nov;16(11):1529-37 - PubMed
  19. Parasitology. 2002 Nov;125(Pt 5):415-21 - PubMed
  20. Nat Rev Immunol. 2006 Jul;6(7):508-19 - PubMed
  21. J Exp Med. 2007 Feb 19;204(2):441-52 - PubMed
  22. J Clin Invest. 1998 Apr 15;101(8):1717-25 - PubMed
  23. J Immunol. 1996 Jul 15;157(2):827-35 - PubMed
  24. N Engl J Med. 1999 Jan 14;340(2):115-26 - PubMed
  25. Circulation. 2004 Feb 24;109(7):893-7 - PubMed
  26. Infect Immun. 2004 Jun;72(6):3571-6 - PubMed
  27. J Vasc Surg. 2006 Jun;43(6):1301-7 - PubMed
  28. Clin Dev Immunol. 2012;2012:865708 - PubMed
  29. J Thromb Haemost. 2009 Jul;7 Suppl 1:328-31 - PubMed
  30. Proc Natl Acad Sci U S A. 1997 Apr 29;94(9):4647-52 - PubMed
  31. Exp Parasitol. 1982 Dec;54(3):397-409 - PubMed
  32. Biochem J. 1966 May;99(2):333-40 - PubMed
  33. Mediators Inflamm. 2011;2011:949072 - PubMed

Publication Types